Eli Lilly and Company’s (LLY) Outperform Rating Reiterated at Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of Eli Lilly and Company (NYSE:LLY – Free Report) in a research report sent to investors on Tuesday, MarketBeat.com reports. They currently have a $1,600.00 target price on the stock.

A number of other analysts have also recently commented on the stock. Citigroup lifted their target price on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Truist Financial restated a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $1,610.00 to $1,700.00 and gave the company a “buy” rating in a research note on Monday, November 9th. Bank of America reaffirmed a “buy” rating and issued a $1,497.00 price target on shares of Eli Lilly and Company in a report on Friday, October 30th. Finally, Weiss Ratings upgraded shares of Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Friday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $1,422.00.

Get Our Latest Stock Report on LLY

Eli Lilly and Company Trading Down 2.2%

Eli Lilly and Company stock opened at $1,352.18 on Tuesday. The stock has a 50-day moving average of $1,263.45 and a two-hundred day moving average of $1,117.53. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,475.25. The stock has a market cap of $1.27 trillion, a PE ratio of 43.89, a price-to-earnings-growth ratio of 1.65 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same quarter last year, the company earned $7.02 earnings per share. The company’s quarterly revenue was up 38.6% on a year-over-year basis. On average, research analysts anticipate that Eli Lilly and Company will post 35.70 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is presently 22.46%.

Insiders Place Their Bets

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the sale, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This trade represents a 54.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently modified their holdings of LLY. JDM Financial Group LLC raised its holdings in Eli Lilly and Company by 66.7% in the 3rd quarter. JDM Financial Group LLC now owns 25 shares of the company’s stock valued at $29,000 after acquiring an additional 10 shares during the last quarter. Torren Management LLC grew its holdings in shares of Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock worth $37,000 after purchasing an additional 25 shares during the period. Foresight Capital Management Advisors Inc. acquired a new stake in shares of Eli Lilly and Company during the third quarter valued at about $49,000. AlphaCentric Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at approximately $42,000. Finally, Sumitomo Mitsui Financial Group Inc. grew its stake in shares of Eli Lilly and Company by 5,100.0% in the third quarter. Sumitomo Mitsui Financial Group Inc. now owns 52 shares of the company’s stock valued at $60,000 after buying an additional 51 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

These are some of the LLY stories that stood out recently:

  • Positive Sentiment: Health Canada approved Mounjaro (tirzepatide) to reduce major cardiovascular risks in adults with type 2 diabetes and established cardiovascular disease, expanding the medicine’s potential use. Health Canada approves Lilly’s Mounjaro to reduce cardiovascular risk
  • Positive Sentiment: Some Wall Street commentary remains bullish: Jefferies reportedly has the highest price target among analysts, and Barclays recently raised its target while maintaining an Overweight rating. Jefferies has Wall Street’s highest target on Eli Lilly
  • Neutral Sentiment: Lilly’s 2026 acquisition spending has surpassed $32 billion, including deals aimed at building cancer and immunology capabilities. The investments could strengthen future growth but also raise execution and capital-allocation questions. Lilly buying spree surpasses $32 billion

About Eli Lilly and Company

(Get Free Report)

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

See Also

Analyst Recommendations for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.